Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

Carole Soussain, Samar Issa, Katharine L Lewis, Christian Grommes, Judith Fox, Renee Ward, Caryn Peterson, Matt Cravets, Anita Mathias, Judith Sosa, Brian J Kirby, Zhaoqing Ding, Isharat Yusuf, Mark J Rose, Marcos W Steinberg, Han W. Tun

Blood (2022) 140 (Supplement 1): 12068–12069.

https://doi.org/10.1182/blood-2022-158599

Published: 2022

Journal Articles

GB5121, a Brain-Penetrant, Irreversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity in a Novel Mouse Model of Intracranial Lymphoma

Isharat Yusuf, Marcos W Steinberg, Maricel Gozo, Bryan Clemons, Kay Hou, David Guimond, Mark J Rose, Kristen Taylor Meadows, Laura Carter

Blood (2022) 140 (Supplement 1): 8878–8879.

https://doi.org/10.1182/blood-2022-159088

Published: 2022

Journal Articles

Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects

Brian J Kirby, Richard Aranda, Renee Ward, Marcos W Steinberg, Maria Hernandez, Judith Sosa, Matt Cravets, Mark J Rose, Robin Osterhout, Zhaoqing Ding, Isharat Yusuf, Judith Fox, Anita Mathias

Blood (2022) 140 (Supplement 1): 11570–11571.

https://doi.org/10.1182/blood-2022-160388

Published: 2022

Journal Articles

KLF4 suppresses transformation of pre-B cells by ABL oncogenes

Michael G. Kharas, Isharat Yusuf, Vanessa M. Scarfone, Vincent W. Yang, Julia A. Segre, Claudia S. Huettner, David A. Fruman

Blood (2006) 109 (2): 747–755.

https://doi.org/10.1182/blood-2006-03-011106

Published: 2006

Journal Articles

Optimal B-cell proliferation requires phosphoinositide 3-kinase–dependent inactivation of FOXO transcription factors

Isharat Yusuf, Xiaocui Zhu, Michael G. Kharas, Jing Chen, David A. Fruman

Blood (2004) 104 (3): 784–787.

https://doi.org/10.1182/blood-2003-09-3071

Published: 2004

NARROW

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

GB5121, a Brain-Penetrant, Irreversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity in a Novel Mouse Model of Intracranial Lymphoma

Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects

KLF4 suppresses transformation of pre-B cells by ABL oncogenes

Optimal B-cell proliferation requires phosphoinositide 3-kinase–dependent inactivation of FOXO transcription factors

Email alerts

ASH Publications

American Society of Hematology

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

GB5121, a Brain-Penetrant, Irreversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity in a Novel Mouse Model of Intracranial Lymphoma

Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects

KLF4 suppresses transformation of pre-B cells by ABL oncogenes

Optimal B-cell proliferation requires phosphoinositide 3-kinase–dependent inactivation of FOXO transcription factors

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only